PAREXEL APPOINTS TODD A. JORON AS CORPORATE VICE PRESIDENT AND GENERAL MANAGER OF PERCEPTIVE INFORMATICS, INC.
BOSTON, MA, December 12, 2005 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that Todd A. Joron, MBA, has been appointed to the role of Corporate Vice President and General Manager of Perceptive Informatics, Inc., a wholly-owned subsidiary of PAREXEL that provides technology products and services. Mr. Joron will manage Perceptive’s global offerings that include Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and Integration Services.
“We expect that Todd’s focused leadership will continue to help us capitalize on the significant market opportunity that exists for Perceptive. His managerial and scientific expertise and technical knowledge will enhance Perceptive’s ability to deliver technology and services that optimize the process of product development and commercialization for our clients,” said Mark A. Goldberg, MD, President of Clinical Research Services and Perceptive Informatics.
Mr. Joron has 20 years of experience within international companies specializing in the design, development and implementation of informatics solutions for the pharmaceutical and healthcare industries. Mr. Joron joins PAREXEL from Management Science Associates, Inc. (MSA), where he was Vice President and Scientific Director of the Life Sciences Software Division. Previously, he was Senior Vice President of Sales and Marketing at TissueInformatics Inc., a medical image analysis software company. Mr. Joron also previously served as President and CEO of BiblioMondo, an international software company, and was formerly General Manager of the scientific software division within MDS Pharma Services (formerly Phoenix International Life Sciences), a multinational contract research organization. Mr. Joron holds a college degree in health sciences and a Masters degree in Business Administration.
Mr. Joron is based in the Waltham, Massachusetts office of Perceptive Informatics.
About Perceptive Informatics
Perceptive Informatics, Inc. combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive’s portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. IMPACT™ is Perceptive’s market-leading CTMS product with 15,000 users worldwide and INITIATOR™ is a trial management product targeted to the needs of Phase I units. For more information about Perceptive Informatics, visit www.perceptive.com.
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and Integration Services. Headquartered near Boston, Massachusetts, PAREXEL operates in 52 locations throughout 38 countries around the world, and has approximately 5,230 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects”, “targets” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2005 as filed with the SEC on November 9, 2005, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.